Although the high-risk group displays higher immune checkpoint expression, recent studies have indicated that patients with tumors elevated PD-1, PD-L1, or CTLA-4 expression are more likely to benefit from immune checkpoint blockade, as these markers often reflect a suppressed but immunologically active tumor microenvironment [51,52]. This evidence concerns the gene CTLA4 and neoplasm.